Navigation Links
FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
Date:6/1/2009

our study for patients taking VYVANSE during the double-blind treatment period, which were greater than or equal to 2 percent, were insomnia, decreased appetite, and anorexia.

VYVANSE Demonstrated Significant Efficacy Versus Placebo at 13 Hours Postdose

The study that led to this approval of revised labeling for VYVANSE was a randomized, double-blind, placebo-controlled, analog classroom study that assessed the efficacy and safety of VYVANSE in 129 children aged 6 to 12 years with ADHD. Following a four-week, open-label, dose-optimization phase with VYVANSE at 30 mg, 50 mg, and 70 mg doses, patients entered a two-week, double-blind, crossover phase where they were randomized into two groups. One group received their optimal dose of VYVANSE the first week and placebo the second week. The second group received placebo the first week and their optimal dose of VYVANSE the second week.

The primary objective of this study was to assess the time of onset of VYVANSE compared with placebo, as measured by the Swanson, Kotkin, Agler, M-Flynn, and Pelham Deportment (SKAMP-D) rating scale. Secondary objectives included assessment of the duration of efficacy of VYVANSE compared with placebo, as measured by the SKAMP-D scale, and assessment of efficacy and time of onset of VYVANSE compared with placebo as measured by SKAMP Attention (SKAMP-A), and Permanent Product Measure of Performance (PERMP) scales.

In the study, VYVANSE demonstrated significant efficacy versus placebo at 1.5 hours, the first time point measured. Further, VYVANSE treatment was associated with significant efficacy as measured by both subjective (SKAMP-D and SKAMP-A) and objective (PERMP) assessments from the first time point (1.5 hours) through the last time point (13 hours) assessed during the classroom day, and at all time points in between (2.5, 5.0, 7.5, 10.0 and 12.0 hours).

Safety was also evaluated during the stu
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
2. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
3. Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. FDA Approves Label Change for Non-Invasive Fibroid Treatment
5. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
6. FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
7. FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen
8. European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
9. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
10. FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
11. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: ... and commercializes proprietary technologies and products for advanced microarray ... approved for trading in the United States ... expected to commence on September 17, 2014 on the ... to trade on the TSX Venture Exchange under its ...
(Date:9/17/2014)... 17 de septiembre de 2014  Cryoport, ... proveedor mundial de soluciones logísticas avanzadas criogénicas ... la vida, anunció hoy la contratación de ... con sede en Rótterdam, Países Bajos, para ... Europa en rápido crecimiento. Según los términos ...
(Date:9/17/2014)... , September 17, 2014 ... mode of action from a truly novel ... MGB Biopharma, a biopharmaceutical company ... announces today that it has secured £4.0m ... lead antibacterial, MGB-BP-3, against a range of ...
(Date:9/17/2014)... Cambridge, MA (PRWEB) September 17, 2014 ... and Safety (ACRES) , a multi-stakeholder non-profit collaborative ... and efficiency in clinical research, today announced Phase ... (SASI). , Amir H. Kalali, ... Quintiles and Arti Bajpai, President, Compliance and Quality ...
Breaking Biology Technology:SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4
... April 30 Dendreon Corporation,(Nasdaq: DNDN ) today announced ... Deutsche Bank 33rd Annual Health Care Conference ... ET, Bank of America Health Care Conference Four ... 11:00 a.m. ET, Rodman & Renshaw 5th Annual Global ...
... 3rd Among US For-Profit Healthcare Companies, EL ... provider of kidney care services, announced it has ... Magazine as one of the Top 125,ranking companies ... awarded to organizations that demonstrate a deep,commitment to ...
... Molecular Quantitative Viral Load Assay, ORANGE COUNTY, ... BEC ) announced today that it has ... virus (HCV) from Siemens Healthcare,Diagnostics. Under the agreement, ... viral load HCV blood test for use on ...
Cached Biology Technology:DaVita Honored for 4th Year as Training Top 125 Recipient 2Beckman Coulter Acquires Rights to Hepatitis C Virus 2
(Date:9/17/2014)... EC-FP5 four-year project, delivering its first release in 2004. ... in several EC projects, as a part of the ... BON), to increase the general awareness of the work ... dissemination of the Fauna Europaea results, the ... e-Publishing tools to prepare data papers for all 56 ...
(Date:9/17/2014)... very cleverly, some lessons on how to create the ... Shaw, director of the Optical Technology Center at Montana ... the nanoscale, we,ll discover them." , Some of those ... a conference called "The Nature of Light: Light in ... University of Arizona College of Optical Sciences. The conference ...
(Date:9/17/2014)... research from the Copenhagen Centre for Social Evolution and ... theory that birth weight and -length can partially predict ... such as autism and schizophrenia later in life. The ... and subsequent hospital diagnoses for up to 30 years, ... The study is published today in the Proceedings ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3
... Ants, wasps and humans live in highly complex societies. Our ... trying to find the balance between cooperation and conflict. Understanding ... us key insights into the evolution of sociality in animals. ... biologist Floria Mora-Kepfer Uy, looks at colonies of social wasps ...
... , Press conference announcement: Three years after Fukushima: ... dial-in information, Press room information, Attention PIOs: Sending ... information, Press registration information, Hotel information, U.S. visa ... information about the Ocean Sciences Meeting, please see ...
... powered by methanol or hydrogen have been well studied, ... biomass as a fuel because of the lack of ... researchers at the Georgia Institute of Technology have developed ... converts biomass to electricity with assistance from a catalyst ...
Cached Biology News:What cooperation and conflict in an insect's society can teach us about social acceptance 22014 Ocean Sciences Meeting: Press conference announcement; sending press kits; press registration 22014 Ocean Sciences Meeting: Press conference announcement; sending press kits; press registration 32014 Ocean Sciences Meeting: Press conference announcement; sending press kits; press registration 42014 Ocean Sciences Meeting: Press conference announcement; sending press kits; press registration 5Solar-induced hybrid fuel cell produces electricity directly from biomass 2Solar-induced hybrid fuel cell produces electricity directly from biomass 3
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
...
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
Biology Products: